Abstract
The ATP-synthase inhibitor bedaquiline is effective against drug-resistant tuberculosis but is extremely lipophilic (clogP 7.25) with a very long plasma half-life. Additionally, inhibition of potassium current through the cardiac hERG channel by bedaquiline, is associated with prolongation of the QT interval, necessitating cardiovascular monitoring. Analogues were prepared where the naphthalene C-unit was replaced with substituted pyridines to produce compounds with reduced lipophilicity, anticipating a reduction in half-life. While there was a direct correlation between in vitro inhibitory activity against M. tuberculosis (MIC90) and compound lipophilicity, potency only fell off sharply below a clogP of about 4.0, providing a useful lower bound for analogue design. The bulk of the compounds remained potent inhibitors of the hERG potassium channel, with notable exceptions where IC50 values were at least 5-fold higher than that of bedaquiline. Many of the compounds had desirably higher rates of clearance than bedaquiline, but this was associated with lower plasma exposures in mice, and similar or higher MICs resulted in lower AUC/MIC ratios than bedaquiline for most compounds. The two compounds with lower potency against hERG ex...Continue Reading
References
May 1, 1997·Antimicrobial Agents and Chemotherapy·L Collins, S G Franzblau
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Kanakeshwari FalzariScott G Franzblau
Jan 11, 2007·Antimicrobial Agents and Chemotherapy·Sang Hyun ChoScott G Franzblau
May 15, 2007·Nature Chemical Biology·Anil KoulKoen Andries
Sep 2, 2011·Future Medicinal Chemistry·Jerome GuillemontKoen Andries
Dec 14, 2011·Antimicrobial Agents and Chemotherapy·Marie-Claude RouanKoen Andries
Mar 7, 2012·Antimicrobial Agents and Chemotherapy·A H DiaconD F McNeeley
Aug 13, 2014·Therapeutics and Clinical Risk Management·Eric LeibertWilliam N Rom
Sep 10, 2014·Pharmacotherapy·Marylee V Worley, Sandy J Estrada
Jan 31, 2015·Cold Spring Harbor Perspectives in Medicine·Khisimuzi MdluliAnna Upton
Nov 26, 2015·Science Advances·Laura PreissThomas Meier
Oct 24, 2017·ACS Medicinal Chemistry Letters·Amy S T TongDaniel Conole
Nov 7, 2017·Bioorganic & Medicinal Chemistry Letters·Peter J ChoiBrian D Palmer
Feb 28, 2018·Bioorganic & Medicinal Chemistry·Hamish S SutherlandBrian D Palmer
Citations
Jul 25, 2019·Expert Opinion on Drug Safety·Karen Cohen, Gary Maartens
Nov 13, 2019·Antimicrobial Agents and Chemotherapy·Jickky Palmae SarathyThomas Dick
Jul 4, 2019·SLAS Discovery·Salvatore NesciAlessandra Pagliarani
Jan 23, 2020·Antimicrobial Agents and Chemotherapy·Jickky Palmae SarathyThomas Dick
Jul 31, 2019·Antimicrobial Agents and Chemotherapy·Jickky Palmae SarathyThomas Dick
Jun 12, 2020·The FEBS Journal·Chui-Fann WongGerhard Grüber
Jan 16, 2020·Molecular Diversity·Amaravadhi HarikishoreGerhard Grüber
Apr 5, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Peter J ChoiWilliam A Denny
Sep 22, 2020·Natural Product Research·Ashaimaa Y MoussaAbdel Nasser B Singab
Dec 15, 2019·Antibiotics·Jickky Palmae SarathyThomas Dick
Sep 4, 2020·Pharmaceuticals·Federico AppetecchiaGiovanna Poce
Sep 30, 2020·Antimicrobial Agents and Chemotherapy·Chui-Fann Wong, Gerhard Grüber
Sep 8, 2019·European Journal of Medicinal Chemistry·Rakesh NarangSachin Kumar Singh
Jan 11, 2021·European Journal of Medicinal Chemistry·Milan UrbanLucie Brulíková
Oct 3, 2020·Bioorganic & Medicinal Chemistry·Guo-Liang LuBrian D Palmer
Mar 7, 2021·Life Sciences·Aditi ChauhanKajal Kanchan
Dec 8, 2019·Bioorganic & Medicinal Chemistry·Hamish S SutherlandBrian D Palmer
May 26, 2020·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Andrés-Felipe Villamizar-MogotocoroVladimir V Kouznetsov
Apr 14, 2021·Future Medicinal Chemistry·William A Denny
Jul 6, 2021·RSC Medicinal Chemistry·Lisa BarbaroDaniel L Priebbenow
Sep 5, 2020·Current Topics in Medicinal Chemistry·Rishita DeyAnil Kumar Saxena